Adagio Therapeutics总结了ADG20对新冠病毒变种的中和活性，并概述了应对奥密克戎的举措
January 13, 2022 19:30 ET
|
Adagio Therapeutics, Inc.
几家独立实验室最近发表的文章表明，ADG20具有中和活性，其效力可与其他针对奥密克戎的保有活性抗体相媲美 目前正在进行多项努力来应对奥密克戎和潜在的新冠病毒变种 马萨诸塞州沃尔瑟姆, Jan. 14, 2022 (GLOBE NEWSWIRE) -- 专注于发现、开发和商业化具有疫情潜力传染病抗体解决方案的临床阶段生物制药公司Adagio Therapeutics,...
Adagio Therapeutics Divulga Resumo da Atividade Neutralizante do ADG20 Contra Variantes do SARS-CoV-2 e Descreve Iniciativas para Abordar o Omicron
January 13, 2022 19:30 ET
|
Adagio Therapeutics, Inc.
Publicações recentes de vários laboratórios independentes mostram que o ADG20 tem atividade neutralizante com potência comparável a outros anticorpos que retêm atividade contra o Omicron Múltiplos...
Adagio Therapeutics Meringkaskan Aktiviti Peneutralan ADG20 Terhadap Varian SARS-CoV-2 dan Menggariskan Inisiatif Menangani Omicron
January 13, 2022 19:30 ET
|
Adagio Therapeutics, Inc.
Penerbitan Terkini oleh Beberapa Makmal Bebas Menunjukkan ADG20 Mempunyai Aktiviti Yang Meneutralkan dengan Potensi Setanding dengan Antibodi Lain yang Mengekalkan Aktiviti Melawan Omicron Pelbagai...
Adagio Therapeutics, SARS-CoV-2 변이에 대한 ADG20의 중화 활동 종합 보고 및 Omicron 대응 계획 발표
January 13, 2022 19:30 ET
|
Adagio Therapeutics, Inc.
여러 독립 시험기관의 연구 결과, ADG20의 중화 활동 능력치는 Omicron 중화 활동 보유한 기타 항체에 필적할 수준 Omicron 및 기타 SARS-CoV-2 변이 가능성에 대처하기 위해 다각도로 노력 중 미국 매사추세츠주 월섬, Jan. 14, 2022 (GLOBE NEWSWIRE) -- 임상 단계 바이오 제약사로 팬데믹으로 변질 우려가...
Adagio Therapeutics、SARS-CoV-2変異株に対するADG20中和活性の概要とオミクロン株に対処するための取り組みを発表
January 13, 2022 19:30 ET
|
Adagio Therapeutics, Inc.
複数の独立した研究機関による最近の発表によると、ADG20は、オミクロン株に対する活性を保持する他の抗体と同等の効力の中和活性を有する オミクロン株および将来発生する可能性のあるSARS-CoV-2変異株に対応するための複数の取り組みが実施されている マサチューセッツ州ウォルサム発, Jan. 14, 2022 (GLOBE NEWSWIRE) --...
Online Festivals Soar, Omicron Surges, and Sundance goes Full Stream Ahead
January 13, 2022 14:53 ET
|
Shift72
HAMILTON, New Zealand, Jan. 13, 2022 (GLOBE NEWSWIRE) -- With Omicron cases surging to record highs, Shift72 is seeing an influx in enquiries from global film festivals who are seeking – or...
MAKO Medical Exceeds 10 Million COVID-19 Tests
January 10, 2022 06:30 ET
|
MAKO Medical
Raleigh, North Carolina, Jan. 10, 2022 (GLOBE NEWSWIRE) -- MAKO Medical Laboratories, a national reference laboratory and leader in COVID-19 testing, today announced that it has surpassed another...
First Wave BioPharma Completes Enrollment for Part 2 of RESERVOIR Phase 2 Trial Evaluating FW-COV in COVID-19-Related GI Infections
January 06, 2022 07:00 ET
|
First Wave BioPharma, Inc.
No Drug-Related SAEs Reported; Topline Data Expected 1H 2022 Part 2 of RESERVOIR Trial to Evaluate Efficacy of FW-COV, an Oral Formulation of Niclosamide, and Expand Safety Observations on...
Expanding the Success of Famileo: Still Bringing Residents and Families Together!
January 05, 2022 14:42 ET
|
Signature Healthcare
Louisville, KY., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Signature HealthCARE’s residents and families have been nothing short of resilient during our on-going pandemic in a number of ways, including...
First Wave BioPharma to Participate in Two Investor Conferences in January 2022
January 04, 2022 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Jan. 04, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...